New influenza and RSV research offers clinically relevant insights into vaccine performance and outbreak prevention. This roundup examines an investigational mRNA flu vaccine, rapid oseltamivir use in...
A real-world analysis found that mRNA SARS-CoV-2 vaccination was associated with lower 3-year mortality after CAR T-cell therapy in patients with hematologic malignancies.
A retrospective surveillance study of critical care units at a tertiary care hospital found high CAUTI/UTI and CLABSI rates, with CLABSI rates increasing 2.64-fold during the COVID-19 era.
June 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.
ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.
Recent studies in children and adults associate long COVID with worsened academic performance, attention difficulties, subjective cognitive impairment, and persistent neurologic and psychiatric symptoms.
...
New reports detail the spread of SARS-CoV-2 variant BA.3.2, Long COVID disability burden, sarbecovirus cross-immunity, and how stacked outpatient risk factors shape severe COVID-19 outcomes.
